Tags

Type your tag names separated by a space and hit enter

[Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients].
Arerugi 2001; 50(6):540-6A

Abstract

Seratrodast, an antagonist to thromboxane A2 (TXA2) receptors, is not always effective in patients with bronchial asthma. In fact, some respond definitely to this drug while others not. In the present study, to clarify the predictability of the clinical effects of Seratrodast, we investigated whether there is a correlation between the levels of TXB2 and 11-DHTXB2, both of which are metabolites of TXA2, in urine and sputum taken before the administration and the clinical effects seen after initiation of the treatment. Baseline concentrations of TXA2 metabolites in urine/sputum were not significantly different between responders and non-responders. However, 4 cases who had remarkably responded to Seratrodast had significantly higher baseline 11-DHTXB2 levels than the rest of the patients. These results suggested that bronchial asthma patients with high urinary 11-DHTXB2 levels could markedly respond to Seratrodast treatment.

Authors+Show Affiliations

Division of Pulmonary Disease, Department of Internal Medicine, Jikei University School of Medicine.No affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

jpn

PubMed ID

11517517

Citation

Muramatsu, H, et al. "[Correlation Between the Clinical Effects of Seratrodast and the Level of 11-dehydrothromboxane B2 in Urine/sputum in Bronchial Asthma Patients]." Arerugi = [Allergy], vol. 50, no. 6, 2001, pp. 540-6.
Muramatsu H, Kotajima R, Sato T. [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. Arerugi. 2001;50(6):540-6.
Muramatsu, H., Kotajima, R., & Sato, T. (2001). [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. Arerugi = [Allergy], 50(6), pp. 540-6.
Muramatsu H, Kotajima R, Sato T. [Correlation Between the Clinical Effects of Seratrodast and the Level of 11-dehydrothromboxane B2 in Urine/sputum in Bronchial Asthma Patients]. Arerugi. 2001;50(6):540-6. PubMed PMID: 11517517.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Correlation between the clinical effects of Seratrodast and the level of 11-dehydrothromboxane B2 in urine/sputum in bronchial asthma patients]. AU - Muramatsu,H, AU - Kotajima,R, AU - Sato,T, PY - 2001/8/24/pubmed PY - 2001/9/28/medline PY - 2001/8/24/entrez SP - 540 EP - 6 JF - Arerugi = [Allergy] JO - Arerugi VL - 50 IS - 6 N2 - Seratrodast, an antagonist to thromboxane A2 (TXA2) receptors, is not always effective in patients with bronchial asthma. In fact, some respond definitely to this drug while others not. In the present study, to clarify the predictability of the clinical effects of Seratrodast, we investigated whether there is a correlation between the levels of TXB2 and 11-DHTXB2, both of which are metabolites of TXA2, in urine and sputum taken before the administration and the clinical effects seen after initiation of the treatment. Baseline concentrations of TXA2 metabolites in urine/sputum were not significantly different between responders and non-responders. However, 4 cases who had remarkably responded to Seratrodast had significantly higher baseline 11-DHTXB2 levels than the rest of the patients. These results suggested that bronchial asthma patients with high urinary 11-DHTXB2 levels could markedly respond to Seratrodast treatment. SN - 0021-4884 UR - https://www.unboundmedicine.com/medline/citation/11517517/[Correlation_between_the_clinical_effects_of_Seratrodast_and_the_level_of_11_dehydrothromboxane_B2_in_urine/sputum_in_bronchial_asthma_patients]_ L2 - http://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -